FIELD: chemistry.
SUBSTANCE: invention relates to a salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid, a method of producing said salt, as well as a method of correcting metabolic disorders in case of sugar diabetes with diabetes with exogenous hypercholesteremia and morphofunctional disorders and brain during acute ischemia.
EFFECT: novel salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid is described, which has hypoglycemic, hypolipidemic and neuroprotective activity and can be used in endocrinology, cardiology, neurology, emergency treatment and intensive care.
4 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
2-ETHYL-6-METHYL-3-HYDROXYLIRIDINIUMHYDROXYBUTANEDIOAT EXPRESSING ANTI-ISHEMIC, CEREBROPROTECTIVE, NEUROTROPIC AND LIPID-REGULATING ACTIVITY, PHARMACEUTICAL COMPOSITIONS AND MEDICAL PRODUCT | 2008 |
|
RU2377237C1 |
MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
AGENT POSSESSING ANTIRADICAL, CEREBROPROTECTIVE AND ANTIISCHEMIC PROPERTIES | 2010 |
|
RU2445090C1 |
AGENT POSSESSING CARDIO-, NEPHRO-, ENDOTHELIAL-, MICROANGIO-, MACROANGIO- AND ENCEPHALOPROTECTIVE PROPERTIES | 2018 |
|
RU2700791C1 |
ANTIOXIDANT, STRESS AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT SODIUM COMENATE | 2012 |
|
RU2506078C1 |
AGENT POSSESSING ENDOTHELIUM PROTECTIVE EFFECT IN CONDITIONS OF EXPERIMENTAL DIABETES MELLITUS AND CEREBRAL BLOOD CIRCULATION DISORDER | 2015 |
|
RU2601622C1 |
ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT POTASSIUM COMENATE | 2012 |
|
RU2514632C1 |
MEDICINAL AGENT FOR PREVENTING AND TREATING CEREBRAL DISEASES AND METHOD OF TREATING CEREBRAL DISEASES | 2015 |
|
RU2692063C2 |
PHARMACEUTICAL COMBINATION OF ATORVASTATIN AND NICERGOLIN FOR PREVENTING OR TREATING CEREBROVASCULAR DISEASE | 2011 |
|
RU2481124C1 |
METHOD FOR PREVENTION OF BRAIN ISCHEMIA | 2017 |
|
RU2642961C1 |
Authors
Dates
2012-06-27—Published
2010-07-09—Filed